3 active not recruiting, 2 completed, 1 terminated. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
| Phase 1 | 3 | Active not recruiting 2, Terminated 1 |
Follow Ann Arbor Stage IV Non-Hodgkin Lymphoma: new trials by email Literature Review of Ann Arbor Stage IV Non-Hodgkin Lymphoma trials Research Report on Ann Arbor Stage IV Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 83 | 2010-11-15 | 2026-10-22 |
| Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 81 | 2008-08-18 | 2026-08-19 |
Lymphoma, Non-Hodgkin (4) · Central Nervous System Neoplasms (3) · Ependymoma (3) · Glioma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Medulloblastoma (3) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Osteosarcoma (3) · Rhabdoid Tumor (3) · Rhabdomyosarcoma (3) · Sarcoma (3) · Sarcoma, Ewing (3) · Wilms Tumor (3)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
Doxorubicin (3) · Specimen Handling (3) · Cyclophosphamide (2) · LY3023414 (2) · Magnetic Resonance Spectroscopy (2) · Phantoms, Imaging (2) · Vemurafenib (2) · Vorinostat (2) · X-Rays (2) · olaparib (2) · palbociclib (2) · tazemetostat (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Ado-Trastuzumab Emtansine (1)
National Cancer Institute (NCI) (5) · OHSU Knight Cancer Institute (1)
United States (6) · Puerto Rico (3) · Australia (1) · Canada (1)
Daniel O Persky (1) · Donald W Parsons (1) · Lara Davis, MD (1) · Mark N Stein (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 33591402, PMID 35353553, PMID 39863139, PMID 41166674, PMID 42686334
U10CA180886 (3), P30CA072720 (1), U01CA099118 (1), U01CA132194 (1), U10CA032102 (1), U10CA180888 (1), UM1CA186716 (1)